Advertisement

Immunopathology of Pulmonary Granulomas

  • Quentin N. Myrvik
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 155)

Abstract

Granulomatous-type inflammations can be divided into two general categories: (a) nonimmunologic or foreign body type and (b) immunologic or hypersensitivity type. The foreign body type granulomas are readily produced experimentally with substances like carrageenan, plastic beads, bentonite, talc and certain microbial cell-wall products, such as mycobacterial cord factor. The major principle involved in these types of granulomas is that the irritant is usually water insoluble and slowly digestible or nondigestible. Accordingly, it represents the basic cellular response of chronic inflammation which is dominated by macrophage mobilization to the site of the irritant. As a rule, the lymphocyte response is minimal and the level of macrophage activation is limited. The characteristic response in this case is that repeated injections of these types of irritants produce the same time course in the evolution of the lesion (1).

Keywords

Central Necrosis Foreign Body Granuloma Plastic Bead Granulomatous Response Bowman Gray School 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Boros, Dov L., in “Granulomatous Inflammations” (P. Kallos, ed.), Progress in Allergy, Vol. 24, pp. 183-267, S. Karger, Basel, 1978.Google Scholar
  2. 2.
    Spector, W. G., and Lykke, A. W. J., J. Path. Bact. 92:163, 1966.PubMedCrossRefGoogle Scholar
  3. 3.
    Spector, W. G., and Ryan, G. B., in “Mononuclear Phagocytes” (van Furth, ed.), Davis, Philadelphia, 1970.Google Scholar
  4. 4.
    Spector, W. G., Lykke, A. W. J., and Willoughby, D. A., J. Path. Bact. 93:101, 1967.PubMedCrossRefGoogle Scholar
  5. 5.
    McGee, M. P., and Myrvik, Q. N., J. Reticuloendothelial Soc. 22:253, 1978.Google Scholar
  6. 6.
    McGee, M. P., and Myrvik, Q. N., Infect. Immun. 26:910, 1979.PubMedGoogle Scholar
  7. 7.
    Galindo, B., Myrvik, Q. N., Love, S. H., J. Reticuloendothelial Soc. 18:295. 1975.Google Scholar
  8. 8.
    Love, S. H., Shannon, B. T., Myrvik, Q. N., and Lynn, W. S., J. Reticuloendothelial Soc. 25:269, 1979.Google Scholar
  9. 9.
    Yamamura, T., Ogawa, Y., Maeda, H., and Yamamura, Y., Amer. Rev. Resp. Dis. 109:594, 1974.PubMedGoogle Scholar
  10. 10.
    Herscowitz, H. B., Conrad, R. E., and Penline, K. J., Adv. Exp. Med. Biol. 121A:459, 1980.Google Scholar
  11. 11.
    Ansfield, M. J., Kaltreider, H. B., Caldwell, J. L., and Herskowitz, F. N., J. Immunol. 122:542, 1979.PubMedGoogle Scholar
  12. 12.
    Demenkoff, J. H., Ansfield, M. J., Kaltreider, H. B., and Adam, E., J. Immunol. 124:1365, 1980.PubMedGoogle Scholar
  13. 13.
    Doughty, B. L., and Phillips, S., J. Immunol. 128:37, 1982.PubMedGoogle Scholar
  14. 14.
    Jungi, T. W., J. Reticuloendothelial Soc. 30:33, 1981.Google Scholar
  15. 15.
    Lipscomb, M. F., Myons, C. R., O’Hara, R. M Jr., and Stein-Streilein, J., J. Immunol. 128:111, 1982.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Quentin N. Myrvik
    • 1
  1. 1.Department of Microbiology and ImmunologyBowman Gray School of MedicineWinston-SalemUSA

Personalised recommendations